E154 - (CME) The Efficacy and Safety of VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
NEI Podcast
00:00
Tetrebenazine
Tetrobenisin was actually approved in a few countries for the treatment of t d before it became available formarly. The problem with tetrebenazine is that very short half life. That means you have to take it three or four times a day. There are two medications that are essentially derived from tetrabenazine that get approved? Yes, there are.
Transcript
Play full episode
